Es un componente crucial de la produccin de energa en el cuerpo
As GLP-1 RAs are contraindicated for people with gastrointestinal disease, pancreatitis, or a family history of mutations in multiple endocrine neoplasia type 2/medullary thyroid carcinoma (MEN2/MTC), SGLT2i is the preferred treatment for these patients groups
No established evidence shows that GLP-1 receptor agonists increase the risk of blood clots
Demand Analysis for GLP-1 Nutritional Support Market in China The China market rose from approximately 10.8% in 2020 to 2024 to 15.4% during 2025 to 2035, fueled by government-led metabolic health programs and expansion in GLP-1 drug coverage
The most common side effects include: Nausea Reduced appetite Diarrhea Vomiting Constipation Abdominal pain Headache These side effects are generally mild to moderate in severity and often diminish as the body adjusts to the medication over time
Numerous endogenous peptides meet fundamental criteria for druggability, including defined receptors, dose-dependent physiological effects, and genetic or pharmacologic validation in preclinical models
